Fig. 1: XPO1 and Bcl-xL inhibitors synergistically induce apoptosis in cancer cells. | Cell Death & Disease

Fig. 1: XPO1 and Bcl-xL inhibitors synergistically induce apoptosis in cancer cells.

From: XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

Fig. 1

a, b U87, U251, and H1299 cells were treated with indicated dose of LMB or KPT-330 for 48 h and subjected to western blot. c Four glioblastoma, two NSCLC, and one cervical cancer cell lines were treated with indicated dose of KPT-330 together with 1 μM of ABT-199, A-1331852, or ABT-263 for 48 h. Cell viability was measured by the MTT assay (mean ± SD, n = 3). d U87, U251, H1299, and A549 cells were treated with KPT-330 (1 μM) for 24 h and further with A-1155463 (1 μM) or A-1331852 (1 μM) for 24 h, then subjected to western blot or flow cytometry analysis for the sub-G1 phase (mean ± SD, n = 3). *P < 0.05. e Cell lines in c were treated with indicated dose of KPT-330 or A-1331852 or both for 48 h. Cell viability was measured by the MTT assay. Combination index (CI) at ED50 was calculated by ComboSyn software with the Chou-Talaley equation (mean ± SD, n = 3). f The mitochondrial membrane potential in U251 cells treated as in d was measured by flow cytometry (mean ± SD, n = 3). *P < 0.05. GAPDH was used as the loading control

Back to article page